Heated Chemotherapy (HITHOC and HIPEC) - Revision history

MesotheliomaSupport: Fix structural reference errors: remove 4 orphaned refs (RON-2026-04-05-003)

2026-04-06T10:03:53Z

Fix structural reference errors: remove 4 orphaned refs (RON-2026-04-05-003)

← Older revision		Revision as of 10:03, 6 April 2026
Line 375:		Line 375:
	<ref name="jtd_ncdb">[https://jtd.amegroups.com/article/view/80136/html Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) During Resection of Pleural Mesothelioma on Patient Survival], Journal of Thoracic Disease (2023)</ref>		<ref name="jtd_ncdb">[https://jtd.amegroups.com/article/view/80136/html Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) During Resection of Pleural Mesothelioma on Patient Survival], Journal of Thoracic Disease (2023)</ref>
	<ref name="wjso_systematic">[https://wjso.biomedcentral.com/articles/10.1186/s12957-025-03748-8 Hyperthermic Intrathoracic Chemotherapy in Patients with Malignant Pleural Mesothelioma: A Systematic Review], World Journal of Surgical Oncology (2025)</ref>		<ref name="wjso_systematic">[https://wjso.biomedcentral.com/articles/10.1186/s12957-025-03748-8 Hyperthermic Intrathoracic Chemotherapy in Patients with Malignant Pleural Mesothelioma: A Systematic Review], World Journal of Surgical Oncology (2025)</ref>
	<ref name="medrxiv_pilot">[https://medrxiv.org/lookup/doi/10.1101/2021.11.27.21265291 Comparison of VATS P/D Surgery plus HITHOC with VATS Talc Pleurodesis for MPM: A Randomized Pilot Study], medRxiv (2021)</ref>
	<ref name="springer_egyptian">[https://link.springer.com/10.1007/s13304-024-01986-1 Effect of Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for MPM: A Comparative Study], Updates in Surgery (2024)</ref>		<ref name="springer_egyptian">[https://link.springer.com/10.1007/s13304-024-01986-1 Effect of Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for MPM: A Comparative Study], Updates in Surgery (2024)</ref>
	<ref name="pmc_egyptian">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11628442/ Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for Malignant Pleural Mesothelioma], PMC / National Library of Medicine (2024)</ref>		<ref name="pmc_egyptian">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11628442/ Intraoperative Hyperthermic Intrathoracic Chemotherapy After Pleurectomy Decortication for Malignant Pleural Mesothelioma], PMC / National Library of Medicine (2024)</ref>
Line 382:		Line 381:
	<ref name="wake_forest">[https://pmc.ncbi.nlm.nih.gov/articles/PMC10249750/ Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center], Annals of Surgical Oncology (2023)</ref>		<ref name="wake_forest">[https://pmc.ncbi.nlm.nih.gov/articles/PMC10249750/ Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center], Annals of Surgical Oncology (2023)</ref>
	<ref name="jco_yan">[https://ascopubs.org/doi/10.1200/JCO.2009.23.9640 Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience], Journal of Clinical Oncology (2009)</ref>		<ref name="jco_yan">[https://ascopubs.org/doi/10.1200/JCO.2009.23.9640 Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience], Journal of Clinical Oncology (2009)</ref>
	<ref name="pmc_alexander">[https://pmc.ncbi.nlm.nih.gov/articles/PMC3734959/ Treatment Factors Associated with Long-Term Survival After CRS and Regional Chemotherapy for Malignant Peritoneal Mesothelioma], PMC / National Library of Medicine</ref>
	<ref name="cureus_india">[https://www.cureus.com/articles/312878 Cytoreductive Surgery and HIPEC for Peritoneal Mesothelioma: Outcomes from a Tertiary Cancer Care Center in India], Cureus</ref>		<ref name="cureus_india">[https://www.cureus.com/articles/312878 Cytoreductive Surgery and HIPEC for Peritoneal Mesothelioma: Outcomes from a Tertiary Cancer Care Center in India], Cureus</ref>
	~~<ref name="asco_roswell">[https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.816 CRS with HIPEC in Malignant Peritoneal Mesothelioma], ASCO Abstract (2026)</ref>~~
	<ref name="pmc_nephrotoxicity">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11242517/ Nephrotoxicity Associated with Cytoreductive Surgery Combined with HIPEC], PMC / National Library of Medicine</ref>		<ref name="pmc_nephrotoxicity">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11242517/ Nephrotoxicity Associated with Cytoreductive Surgery Combined with HIPEC], PMC / National Library of Medicine</ref>
	<ref name="amjcr_bidirectional">[https://amjcaserep.com/abstract/full/idArt/938192 Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide], American Journal of Case Reports</ref>		<ref name="amjcr_bidirectional">[https://amjcaserep.com/abstract/full/idArt/938192 Bidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide], American Journal of Case Reports</ref>
Line 406:		Line 403:
	<ref name="mesoatty_treatment">[https://mesotheliomaattorney.com/mesothelioma/treatment/ Mesothelioma Treatment Overview], MesotheliomaAttorney.com</ref>		<ref name="mesoatty_treatment">[https://mesotheliomaattorney.com/mesothelioma/treatment/ Mesothelioma Treatment Overview], MesotheliomaAttorney.com</ref>
	<ref name="mesoatty_claims">[https://mesotheliomaattorney.com/asbestos-trust-funds/ Asbestos Trust Funds], MesotheliomaAttorney.com</ref>		<ref name="mesoatty_claims">[https://mesotheliomaattorney.com/asbestos-trust-funds/ Asbestos Trust Funds], MesotheliomaAttorney.com</ref>
	~~<ref name="cancer_gov">[https://www.cancer.gov/types/mesothelioma Mesothelioma Treatment], National Cancer Institute</ref>~~
	</references>		</references>

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T21:01:39Z

Internal linking: added 3 wiki links

← Older revision		Revision as of 21:01, 20 February 2026
Line 43:		Line 43:
	== Executive Summary ==		== Executive Summary ==

	Heated chemotherapy represents one of the most significant advances in mesothelioma treatment, combining cytoreductive surgery with high-concentration chemotherapy solutions heated to 40–43°C and circulated directly within the body cavity where the tumor originated. Two distinct procedures have emerged for the two primary forms of mesothelioma: Hyperthermic Intrathoracic Chemotherapy (HITHOC) for [[Pleurectomy_and_Decortication\|pleural mesothelioma]] and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal mesothelioma.<ref name="pmc_hipec_rationale" /><ref name="dandell_treatment" />		Heated chemotherapy represents one of the most significant advances in [[Mesothelioma\|mesothelioma]] treatment, combining cytoreductive surgery with high-concentration chemotherapy solutions heated to 40–43°C and circulated directly within the body cavity where the tumor originated. Two distinct procedures have emerged for the two primary forms of mesothelioma: Hyperthermic Intrathoracic Chemotherapy (HITHOC) for [[Pleurectomy_and_Decortication\|pleural mesothelioma]] and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for [[Peritoneal Mesothelioma\|peritoneal mesothelioma]].<ref name="pmc_hipec_rationale" /><ref name="dandell_treatment" />

	The scientific rationale is compelling: hyperthermia selectively destroys cancer cells at temperatures that normal tissue can tolerate, while simultaneously increasing drug penetration from approximately 1–2 mm to up to 5 mm into tumor tissue. For pleural mesothelioma, a National Cancer Database analysis of 3,232 patients found HITHOC independently improved overall survival (HR 0.80, p=0.002), with a median of 20.5 months versus 16.8 months without HITHOC. For peritoneal mesothelioma, CRS-HIPEC has transformed outcomes from a median survival of under 12 months to 53 months in the landmark multi-institutional registry, with 5-year survival rates reaching 47%.<ref name="jtd_ncdb" /><ref name="jco_yan" /><ref name="mlc_treatment" />		The scientific rationale is compelling: hyperthermia selectively destroys cancer cells at temperatures that normal tissue can tolerate, while simultaneously increasing drug penetration from approximately 1–2 mm to up to 5 mm into tumor tissue. For [[Pleural Mesothelioma\|pleural mesothelioma]], a National Cancer Database analysis of 3,232 patients found HITHOC independently improved overall survival (HR 0.80, p=0.002), with a median of 20.5 months versus 16.8 months without HITHOC. For peritoneal mesothelioma, CRS-HIPEC has transformed outcomes from a median survival of under 12 months to 53 months in the landmark multi-institutional registry, with 5-year survival rates reaching 47%.<ref name="jtd_ncdb" /><ref name="jco_yan" /><ref name="mlc_treatment" />

	At experienced high-volume centers, 30-day mortality for both HITHOC and HIPEC ranges from 2% to 4%, and patients achieving complete cytoreduction with HIPEC have achieved median survival exceeding 10 years. The completeness of tumor removal and histologic subtype remain the most powerful predictors of outcome for both procedures.<ref name="wake_forest" /><ref name="mesonet_treatment" />		At experienced high-volume centers, 30-day mortality for both HITHOC and HIPEC ranges from 2% to 4%, and patients achieving complete cytoreduction with HIPEC have achieved median survival exceeding 10 years. The completeness of tumor removal and histologic subtype remain the most powerful predictors of outcome for both procedures.<ref name="wake_forest" /><ref name="mesonet_treatment" />

MesotheliomaSupport: New page: Heated chemotherapy guide covering HITHOC for pleural and HIPEC for peritoneal mesothelioma with survival data, patient selection, and clinical trials

2026-02-20T04:34:58Z

New page: Heated chemotherapy guide covering HITHOC for pleural and HIPEC for peritoneal mesothelioma with survival data, patient selection, and clinical trials

Show changes